Oncology Venture, Innovation & Partnering Summit 2024
ÀÏÁ¤ : 2024³â 10¿ù 9-10ÀÏ
°³ÃÖ: Royal Sonesta Cambrige, Cambrige, USA
ÇØ´ç ÄÁÆÛ·±½º´Â Á¾·áµÇ¾ú½À´Ï´Ù.
Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English_

ÅõÀÚÀÚ¿Í ºñÁî´Ï½º ¸®´õ¸¦ ¿¬°á½ÃÄÑ ¾Ï ºÐ¾ßÀÇ Çõ½Å °¡¼Ó

ÀÌ ÄÁÆÛ·±½º´Â »ó±Þ ·¹º§ ÅõÀÚÀÚ ¹× ±â¾÷ ÀÓ¿ø, ±â¾÷°¡, ºñÁî´Ï½º ¸®´õ°¡ Âü°¡Çϴ Ưº° À̺¥Æ®ÀÔ´Ï´Ù. Ä£¹ÐÇÑ ºÐÀ§±âÀÇ ³×Æ®¿öÅ· ¼¼¼Ç¿¡¼­´Â ¹Ì·¡ÀÇ ÅõÀÚÀÚ ¹× ÆÄÆ®³Ê¿Í Á¢ÃËÇÒ ¼ö ÀÖÀ¸¸ç, ¾÷°è°¡ ÁÖµµÇÏ´Â ÆгΠµð½ºÄ¿¼Ç¿¡¼­´Â ¾ÏÄ¡·á¡¤Áø´Ü¿¡ °üÇÑ ÀÚ±ÝÁ¶´Þ È°µ¿¡¤¸ñÇ¥¡¤»ç¾÷ ¹ßÀü¿¡ °üÇÑ Àü·«Àû ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖÀ¸¸ç, ¿ªµ¿ÀûÀÎ ÆÄÀ̾î»çÀ̵å ê¿¡¼­´Â Á¾¾ç ¾÷°èÀÇ ¿ÀÇǴϾ𠸮´õ·ÎºÎÅÍ ¼ÖÁ÷ÇÑ °ßÇØ ¹× ºñÁî´Ï½º»ó Á¦¾ÈÀ» µéÀ» ¼ö ÀÖ½À´Ï´Ù.

Cambridge Innovation Institute´Â ¾Ï Ä¡·áÁ¦¡¤Áø´Ü¾à °³¹ßÀÇ ¸ðµç Ãø¸éÀ» ´Ù·ç´Â ÃÖ÷´Ü ¹ÌÆÃÀ» 30³â ÀÌ»ó Á¦ÀÛÇÏ°í ÀÖÀ¸¸ç, ½ÇÀûÀ» ±â¹ÝÀ¸·Î ¾Ï¿µ¿ªÀÇ »ç¾÷ ¹ßÀüÀ» Àü¹®À¸·Î ÇÏ´Â Áß¿äÇÑ ÄÁÆÛ·±½º¸¦ °³ÃÖÇÕ´Ï´Ù. ÀÌ ÄÁÆÛ·±½º´Â 2024³â 10¿ù 9-10ÀÏ¿¡ ¸Å»çÃß¼¼Ã÷ÁÖ ÄÉÀӺ긮Áö¿¡¼­ °³Ãֵ˴ϴÙ. ÀÌ ÄÁÆÛ·±½º´Â CII°¡ »õ·Ó°Ô ¼³Ä¡ÇÑ Cambridge VIP divisonÀÇ ÀϺÎÀ̸ç, »ó±Þ ·¹º§ ÅõÀÚÀÚ ¹× ±â¾÷ ÀÓ¿ø, Á¾¾ç ºÐ¾ßÀÇ Çõ½Å¿¡ ÁÖ·ÂÇÏ´Â ½ºÅ¸Æ®¾÷ ¸®´õ µîÀÌ Âü°¡ÇÕ´Ï´Ù. À̹ø ÇÏÀÌ·¹º§ ³×Æ®¿öÅ· À̺¥Æ®´Â ½Ã»çÀûÀÎ ¾÷°è ÁÖµµÇü ÆгΠµð½ºÄ¿¼Ç ¹× ÆÄÀ̾î»çÀ̵å ê, ±×¸®°í ½ºÅ¸Æ®¾÷¡¤ÅõÀÚÀÚ ¹× ÀáÀçÀû ±â¾÷ Àμö°¡°¡ ÀÇ¹Ì ÀÖ´Â °ü°è¸¦ Çü¼ºÇÒ ¼ö ÀÖ´Â ¸¹Àº ³×Æ®¿öÅ·ÀÇ ±âȸ·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÀÌ ÄÁÆÛ·±½º¿¡ Âü°¡ÇÏ¸é »ç¾÷ Çù·Â¡¤ÅõÀÚ ¹× ±â¾÷ Àü·«À» À§ÇÑ ±ÍÁßÇÑ Àü·«Àû ÀλçÀÌÆ®¿Í ¼ÖÁ÷ÇÑ Àü¸Á, ½Ç¿ëÀû ºñÁî´Ï½º»ó Á¦¾ÈÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

ÄÁÆÛ·±½º Ư¡£º

  • Àü¿ë ¸®¼Á¼Ç ¹× ³×Æ®¿öÅ· À̺¥Æ®¿¡¼­ ÅõÀÚÀÚ ¹× CEO, Á¦¾à ¾÷°èÀÇ ¸®´õ¿Í ±³·ùÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • Á¾¾ç ºÐ¾ßÀÇ ºñÁî´Ï½º ¸®´õ·ÎºÎÅÍ ÆгΠµð½ºÄ¿¼ÇÀ» ÅëÇØ ½Çõ °¡´ÉÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.
  • Æí¾ÈÇÑ ºÐÀ§±âÀÇ Fireside Chat¿¡¼­ Á¾¾ç ºÐ¾ßÀÇ ±â¾÷ ÀÓ¿øÀ¸·ÎºÎÅÍ ¹è¿ì°í, »ç¾÷ ¼º°øÀ» À§ÇÑ Àü·«À» ¼ö¸³ÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • °¡Àå ½Ã±âÀûÀýÇÑ ÅäÇÈÀ» ºê·¹ÀνºÅä¹ÖÇÏ°í, Ÿ±ê ¶ó¿îµåÅ×ÀÌºí¿¡¼­ ¹Ì·¡ÀÇ ÆÄÆ®³Ê ¹× ÅõÀÚÀÚ¸¦ ¸¸³¯ ¼ö ÀÖ½À´Ï´Ù.
  • ¿¬°£ ¹ÌÆÿ¡ Âü¿©ÇÏ¿© ¾Ï Çõ½ÅÀ» °¡¼Ó½ÃÅ°¼¼¿ä!

Cambridge VIP Attendee Demographics

VIP Demographics
photo-strip

2024³âµµ ¾ÆÁ¨´Ù ÅäÇÈ£º

  • Future opportunities in oncology investments and strategies to de-risk
    ¾Ï ºÐ¾ßÀÇ ÇâÈÄ ÅõÀÚ¿Í ¸®½ºÅ© Á¦°Å Àü·«
  • Emerging oncology therapeutics and modalities: radiopharmaceuticals, antibody-drug conjugates, CAR T-cell therapy, etc.
    »õ·Î¿î ¾Ï Ä¡·áÁ¦¿Í ¹æ¹ý : ¹æ»ç¼º ÀǾàÇ°, Ç×ü¾à¹°Á¢ÇÕü, CAR-T¼¼Æ÷ Ä¡·á µî
  • Policy implications affecting oncology investors and operators: Inflation Reduction Act, BIOSECURE Act, and an upcoming election
    ¾Ï ºÐ¾ßÀÇ ÅõÀÚÀÚ¡¤°æ¿µÀÚ¿¡ ´ëÇÑ Á¤Ã¥ÀÇ ¿µÇâ : ÀÎÇ÷¹ÀÌ¼Ç »è°¨¹ý(IRA), BIOSECURE¹ý, ÇâÈÄ ¼±°Å
  • Cancer diagnostics, screening, and early detection
    ¾Ï Áø´Ü¡¤½ºÅ©¸®´×¡¤Á¶±â ¹ß°ß
  • Where does Artificial Intelligence add value in oncology: from discovery to care delivery?
    ÀΰøÁö´É(AI)Àº Discovery·ÎºÎÅÍ Ä¡·á Á¦°ø±îÁö Á¾¾ç ºÐ¾ßÀÇ ¾îµð¿¡ °¡Ä¡¸¦ ºÎ°¡Çϴ°¡?
  • Big pharma perspective on oncology venture, partnering, and M&A
    Á¾¾ç ºÐ¾ßÀÇ º¥Ã³¡¤Á¦ÈÞ¡¤M&A¿¡ ´ëÇÑ ´ë±â¾÷ Á¦¾à±â¾÷ÀÇ °ßÇØ
  • Is ¡°precision medicine¡± working?
    'Á¤¹ÐÀÇ·á'´Â ±â´ÉÇÏ°í Àִ°¡?
  • Innovation in oncology clinical trials
    ¾Ï ÀÓ»ó½ÃÇèÀÇ Çõ½Å
  • Improving oncology care delivery and health equity
    ¾Ï Ä¡·á Á¦°ø°ú °Ç°­ ÇüÆò¼ºÀÇ Çâ»ó
  • Ups and downs of immuno-oncology
    ¸é¿ª Á¾¾çÇÐÀÇ ºÎħ
  • How to deliver value-based care in oncology?
    '°¡Ä¡ ±â¹Ý Äɾî(value-based care)'¸¦ Á¾¾çÇп¡¼­ ¾î¶»°Ô Á¦°øÇϴ°¡?


Cambridge VIP Events Testimonials

1 on 1 Networking
Keynote Talks
Panel Discussions
Networking and Reception

Âü°¡ ´ë»óÀÚ

ÅõÀÚ ±â¾÷ :

  • VC/PE/CVC ÅõÀÚÀÚ¡¤¿£Á© ÅõÀÚÀÚ
  • »ó±Þ ·¹º§ ÅõÀÚÀÚ(¸Å´Ï¡ ÆÄÆ®³Ê/µð·ºÅÍ, Á¦³Ê·² ÆÄÆ®³Ê)
  • ÅõÀÚÀÚ(ÆÄÆ®³Ê, ÅõÀÚÀÚ, ´ëÇ¥)
  • Æ÷Æ®Æú¸®¿À ¾îµå¹ÙÀÌÀú(º¥Ã³¡¤¿ÀÆÛ·¹ÀÌÆà ÆÄÆ®³Ê)

½ºÅ¸Æ®¾÷ :

  • ½Å±Ô ±â¾÷
  • ¸®´õ ⸳ÀÚ¡¤CEO
  • ±â¾÷ ÀÓ¿ø(CSO, CIO, CTO µî)
  • Çõ½Å¡¤Àü·« ¸Å´ÏÀú(SVP, VP, µð·ºÅÍ)

±â¾÷ :

  • ÀǾàÇ°¡¤Áø´Ü¾à¡¤ÀÇ·á±â±â ±â¾÷ÀÇ ÀÓ¿ø
  • »ç¾÷°³¹ß Ã¥ÀÓÀÚ(SVP, VP, µð·ºÅÍ)
  • Çõ½Å¡¤Àü·« ¸Å´ÏÀú(SVP, VP, µð·ºÅÍ)
  • º¥Ã³ ¸®´õ(¸Å´Ï¡ µð·ºÅÍ, ÆÄÆ®³Ê, µð·ºÅÍ)